Publications

BibTex format

@article{Fortner:2017:10.1002/ijc.31164,
author = {Fortner, RT and Schock, H and Le, Cornet C and Hüsing, A and Vitonis, AF and Johnson, TS and Fichorova, RN and Fashemi, T and Yamamoto, HS and Tjønneland, A and Hansen, L and Overvad, K and Boutron-Ruault, M-C and Kvaskoff, M and Severi, G and Boeing, H and Trichopoulou, A and Papatesta, E-M and La, Vecchia C and Palli, D and Sieri, S and Tumino, R and Sacerdote, C and Mattiello, A and Onland-Moret, NC and Peeters, PH and Bueno-de-Mesquita, HBA and Weiderpass, E and Quirós, JR and Duell, EJ and Sánchez, M-J and Navarro, C and Ardanaz, E and Larrañaga, N and Nodin, B and Jirström, K and Idahl, A and Lundin, E and Khaw, K-T and Travis, RC and Gunter, M and Johansson, M and Dossus, L and Merritt, MA and Riboli, E and Terry, KL and Cramer, DW and Kaaks, R},
doi = {10.1002/ijc.31164},
journal = {International Journal of Cancer},
pages = {1355--1360},
title = {Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: results from the EPIC cohort},
url = {http://dx.doi.org/10.1002/ijc.31164},
volume = {142},
year = {2017}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to 4 matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated towards the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti-CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76-0.92]; lowest tertile: 0.76 [0.67-0.86]; phet =0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti-CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection. This article is protected by copyright. All rights reserved.
AU  - Fortner,RT
AU  - Schock,H
AU  - Le,Cornet C
AU  - Hüsing,A
AU  - Vitonis,AF
AU  - Johnson,TS
AU  - Fichorova,RN
AU  - Fashemi,T
AU  - Yamamoto,HS
AU  - Tjønneland,A
AU  - Hansen,L
AU  - Overvad,K
AU  - Boutron-Ruault,M-C
AU  - Kvaskoff,M
AU  - Severi,G
AU  - Boeing,H
AU  - Trichopoulou,A
AU  - Papatesta,E-M
AU  - La,Vecchia C
AU  - Palli,D
AU  - Sieri,S
AU  - Tumino,R
AU  - Sacerdote,C
AU  - Mattiello,A
AU  - Onland-Moret,NC
AU  - Peeters,PH
AU  - Bueno-de-Mesquita,HBA
AU  - Weiderpass,E
AU  - Quirós,JR
AU  - Duell,EJ
AU  - Sánchez,M-J
AU  - Navarro,C
AU  - Ardanaz,E
AU  - Larrañaga,N
AU  - Nodin,B
AU  - Jirström,K
AU  - Idahl,A
AU  - Lundin,E
AU  - Khaw,K-T
AU  - Travis,RC
AU  - Gunter,M
AU  - Johansson,M
AU  - Dossus,L
AU  - Merritt,MA
AU  - Riboli,E
AU  - Terry,KL
AU  - Cramer,DW
AU  - Kaaks,R
DO  - 10.1002/ijc.31164
EP  - 1360
PY  - 2017///
SN  - 0020-7136
SP  - 1355
TI  - Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: results from the EPIC cohort
T2  - International Journal of Cancer
UR  - http://dx.doi.org/10.1002/ijc.31164
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29159934
UR  - http://hdl.handle.net/10044/1/54285
VL  - 142
ER  -

Download

ProfessorElioRiboli

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)